Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTIMATE: Envafolimab + Chemoradiotherapy in Rectal Cancer
NCT06239870Phase 2Recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Apr 2023
- Primary completion
- Sep 2025
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in rectal cancer, sponsored by Yunnan Cancer Hospital. Primary endpoint: Pathologic Complete Response at 3 months. Started Apr 2023; status: recruiting.
02
Drugs
envafolimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06239870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239870.